The program aims to advance the understanding of retinal vascular diseases which cause vision loss, including wet age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (RVO).
Additionally, the program expects to investigate the effectiveness and safety of Lucentis in clinical practice across large populations, in order to further enhance patient outcomes.
Novartis Pharma chief scientific officer Timothy Cave said a wealth of data is already available on the safety and efficacy of ranibizumab from clinical trials, but they hope Luminous will further support this data and provide information on the long-term outcomes in clinical practice.